journal article·2018-01-10Open access

Magnetically Coated Bioabsorbable Stents for Renormalization of Arterial Vessel Walls after Stent Implantation

J.S. Lee, P. Han, E. Song, D. Kim, H. Lee, M. Labowsky, J. Taavitsainen, S. Ylä-Herttuala, J. Hytönen, M. Gülcher, K. Perampaladas, A.J. Sinusas, J. Martin, A. Mathur, T.M. Fahmy

Nano Letters· Volume 18· Issue 1

Abstract

The insertion of a stent in diseased arteries is a common endovascular procedure that can be compromised by the development of short- and long-term inflammatory responses leading to restenosis and thrombosis, respectively. While treatment with drugs, either systemic or localized, has decreased the incidence of restenosis and thrombosis these complications persist and are associated with a high mortality in those that present with stent thrombosis. We reasoned that if stents could be made to undergo accelerated endothelialization in the deployed region, then such an approach would further decrease the occurrence of stent thrombosis and restenosis thereby improving clinical outcomes. Toward that objective, the first step necessitated efficient capture of progenitor stem cells, which eventually would become the new endothelium. To achieve this objective, we engineered intrinsic ferromagnetism within nonmagnetizable, biodegradable magnesium (Mg) bare metal stents. Mg stents were coated with biodegradable polylactide (PLA) polymer embedding magnetizable iron–platinum (FePt) alloy nanoparticles, nanomagnetic particles, n Mags, which increased the surface area and hence magnetization of the stent. n Mags uniformly distributed on stents enabled capture, under flow, up to 50 mL/min, of systemically injected iron-oxide-labeled (IO-labeled) progenitor stem cells. Critical parameters enhancing capture efficiency were optimized, and we demonstrated the generality of the approach by showing that n Mag-coated stents can capture different cell types. Our work is a potential paradigm shift in engineering stents because implants are rendered as tissue in the body, and this “natural stealthiness” reduces or eliminates issues associated with pro-inflammatory immune responses postimplantation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Aortic aneurysm repair treatments · Coronary Interventions and Diagnostics · ZnO doping and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, College Station, Texas 77843, United States

Ansama Research LLC, Wayne, New Jersey 07470, United States

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70210, Finland

QualiMed Innovative Medizinprodukte GmbH, Winsen 21423, Germany

Magnus Life Science, Bloomsbury, London WC1E 6JF, United Kingdom

Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London E1 4NS, United Kingdom

References (41)

Show source-provided references
1. 10.1056/NEJMoa160799110.1056/NEJMoa1607991 ↗
2. 10.1038/nrd360410.1038/nrd3604 ↗
3. 10.1016/S0828-282X(09)70073-X10.1016/S0828-282X(09)70073-X ↗
4. 10.1592/phco.31.5.45810.1592/phco.31.5.458 ↗
5. 10.1038/nrcardio.2015.13210.1038/nrcardio.2015.132 ↗
6. 10.1016/S0140-6736(04)17275-910.1016/S0140-6736(04)17275-9 ↗
7. 10.1016/j.amjcard.2006.02.03910.1016/j.amjcard.2006.02.039 ↗
8. Ladich E. · Circulation · 2008 · 118 · S1047
9. 10.1161/01.CIR.100.18.187210.1161/01.CIR.100.18.1872 ↗
10. 10.1161/01.CIR.95.2.43810.1161/01.CIR.95.2.438 ↗
11. 10.1016/S1051-0443(97)70521-910.1016/S1051-0443(97)70521-9 ↗
12. 10.1002/bab.1010.1002/bab.10 ↗
13. 10.1161/01.CIR.80.5.134710.1161/01.CIR.80.5.1347 ↗
14. 10.1016/0002-8703(95)90104-310.1016/0002-8703(95)90104-3 ↗
15. Herring M. · Surgery · 1978 · 84 · 498
16. Belden T. A. · Trans. Am. Soc. Artif. Intern Organs · 1982 · 28 · 173
17. 10.1016/0741-5214(90)90239-710.1016/0741-5214(90)90239-7 ↗
18. 10.1016/j.jacc.2006.06.06910.1016/j.jacc.2006.06.069 ↗
19. 10.3791/5310010.3791/53100 ↗
20. 10.1007/s00392-002-1317-x10.1007/s00392-002-1317-x ↗
21. 10.1038/srep4634310.1038/srep46343 ↗
22. 10.1136/bmj.285.6347.99810.1136/bmj.285.6347.998 ↗
23. 10.1097/00000542-197906000-0000810.1097/00000542-197906000-00008 ↗
24. 10.1016/j.actbio.2014.09.00810.1016/j.actbio.2014.09.008 ↗
25. 10.1016/j.biomaterials.2014.06.03810.1016/j.biomaterials.2014.06.038 ↗
26. 10.1007/s13233-014-2040-y10.1007/s13233-014-2040-y ↗
27. 10.1016/j.biomaterials.2008.10.02110.1016/j.biomaterials.2008.10.021 ↗
28. Heublein B. · Heart · 2003 · 89 · 65110.1136/heart.89.6.651 ↗
29. 10.1016/j.actbio.2015.02.01010.1016/j.actbio.2015.02.010 ↗
30. Hans C. P. · Magnesium Res. · 2003 · 16 · 13
31. Cobbold M. · Blood · 2001 · 98 · 852a
32. Baglin J. E. E. · Mater. Res. Soc. Symp. P · 2003 · 777 · 53
33. 10.1063/1.476197810.1063/1.4761978 ↗
34. 10.1063/1.157650110.1063/1.1576501 ↗
35. 10.1021/jp709889v10.1021/jp709889v ↗
36. 10.1021/nl034734w10.1021/nl034734w ↗
37. 10.1021/jp060974z10.1021/jp060974z ↗
38. 10.1161/01.CIR.0000121732.85572.6F10.1161/01.CIR.0000121732.85572.6F ↗
39. 10.1021/ja905938a10.1021/ja905938a ↗
40. 10.1016/j.jcin.2008.09.01510.1016/j.jcin.2008.09.015 ↗
41. 10.1002/wnan.3810.1002/wnan.38 ↗